fbpx

10-year trial of melanoma vaccine shows most promising outcomes to date

Researchers at the University of Adelaide have discovered a new trial vaccine which offers the most promising treatment to date for advanced melanoma.

Known as ‘vaccinia melanoma cell lysate’ (VMCL), this new trial treatment was given regularly to 54 South Australian patients with advanced, inoperable melanoma over a 10-year period. The vaccine has been found to increase patient survival rates, with the ability to stop or reverse the cancer in some patients.

Continue reading “10-year trial of melanoma vaccine shows most promising outcomes to date”